Return to home page
Searching: Muskingum library catalog
Some OPAL libraries remain closed or are operating at reduced service levels. Materials from those libraries may not be requestable; requested items may take longer to arrive. Note that pickup procedures may differ between libraries. Please contact your library for new procedures, specific requests, or other assistance.
  Previous Record Previous Item Next Item Next Record
  Reviews, Summaries, etc...
Title Tumor targeting in cancer therapy / edited by Michel Page.
Imprint Totowa, N.J. : Humana Press, 2002.

View online
View online
Series Cancer drug discovery and development
Cancer drug discovery and development.
Subject Cancer -- Immunotherapy.
Cancer -- Chemotherapy.
Drug targeting.
Neoplasms -- immunology.
Antibodies, Neoplasm -- therapeutic use.
Antineoplastic Agents -- therapeutic use.
Drug Delivery Systems.
Neoplasms -- therapy.
Alt Name Page, Michel.
Description 1 online resource (x, 463 pages) : illustrations.
Bibliography Note Includes bibliographical references and index.
Access Use copy Restrictions unspecified star
Reproduction Electronic reproduction. [S.l.] : HathiTrust Digital Library, 2010.
System Details Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
Note digitized 2010 HathiTrust Digital Library committed to preserve pda
Print version record.
Contents I.A Review -- 1 The Current Status of Tumor Targeting: A Review -- 2 Clinical Applications of Targeted Therapeutics -- II. Targeting Tumors with Drug Antibody Conjugates -- 3 Targeting the CD22 Receptor with RNA Damaging Agents -- 4 The Development of Liposomes for Enhanced Delivery of Chemotherapeutics to Tumors -- 5 Overcoming Multiple Drug Resistance with Anti-Pgn Carrier -- 6 Targeting with Transferrin -- 7 Synthesis and Evaluation of Paclitaxel Immunoconjugate with Antitumor Activity In Vitro -- 8 The Use of Drug-Monoclonal Antibody Conjugates for the Treatment of Cancer -- III. Targeting Tumors with Antibodies -- 9 Targeting Vascular Endothelium with Antibodies -- 10 Targeting B-Cell Non-Hodgkin's Lymphoma with Monoclonal Antibodies -- 11 From Bench to Bedside: Development of Rituximab (Rituxan), A Monoclonal Antibody for the Therapy of Non-Hodgkin's Lymphoma -- 12 Mylotarg: The First Antibody-Targeted Chemotherapy Agent. -- IV. Targeting Tumors with Radioimmunoconjugates -- 13 188Rhenium-Labeled Trisuccin-?CH2HuCC49 as a Radioimmunotherapy Model in Nude Mice -- V. Targeting Tumors with Immunotoxins -- 14 General Approach for Targeting Toxins -- 15 Antibody-Toxin Conjugates: Chemistry of Coupling and Purification -- 16 Shiga-Like Toxins as Targeted Anticancer Agents -- VI. Targeting Tumors with Antibody-Enzyme Conjugates (ADEPT) -- 17 Antibody-Directed Enzyme Prodrug Therapy with Carboxypeptidase G2: Clinical Studies -- VII. Photodynamic Therapy -- 18 Photodynamic Therapy: Targeting Cancer Cells with Photosensitizer-Bioconjugates -- 19 Tumor Targeting Using PEG-m-THPC for Photodynamic Therapy in a Rat Ovarian-Cancer Model -- VIII. Targeting Tumors with Magnetic Drugs -- 20 Targeting Tumors with Magnetic Drugs -- IX. Principles and Techniques in Targeting -- 21 Internalization of Antibodies -- 22 Bioconjugation and Biodistribution -- 23 Principles of Antitumor Targeting of Cytotoxic Drugs -- 24 Targeting by Antibody or Ligand: Which Is Better?
Summary After many years of vigorous effort, the use of antibodies to target tumors has become highly successful both clinically and commercially. In Tumor Targeting in Cancer Therapy, Dr. Michel Page and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand. Comprehensive and practical, Tumor Targeting in Cancer Therapy summarizes the essentials of tumor targeting as it is practiced today and provides all those engaged in experimental and clinical cancer research the critically established information needed to evaluate new technologies, investigate novel therapeutic agents, and apply them in relevant clinical practice.
ISBN 0585418810 (electronic bk.)
9780585418810 (electronic bk.)
9781617372513 (print)
161737251X (print)
0896039196 (alk. paper)
9780896039193 (alk. paper)
ISBN/ISSN 10.1007/978-1-59259-167-1
OCLC # 50825276
Additional Format Print version: Tumor targeting in cancer therapy. Totowa, N.J. : Humana Press, 2002 0896039196 (DLC) 2001051657 (OCoLC)48177322

If you experience difficulty accessing or navigating this content, please contact the OPAL Support Team